本帖最后由 老马 于 2013-3-13 13:43 编辑
) v! f, d. |& X( U, K, `/ K1 n! K# l2 ~: Z8 p; t" ~
健择(吉西他滨)+顺铂+阿瓦斯汀
6 K( S. {% V' J5 x: G2 t: m( V$ s) i& _6 p Gemzar +Cisplatin + Avastin8 e$ n: Y4 c/ `
http://annonc.oxfordjournals.org/content/21/9/1804.full
, A( n& c' \4 y5 aOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 E$ g: _+ N+ t6 n1 R2 A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, o8 z+ A, r V+ l6 RResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 4 d! O# ?5 ^" ^8 b- v
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 836)
, ]7 L7 N* [/ [( m华为网盘附件:
P: F. U2 W" H【华为网盘】ava.JPG
6 s7 Y8 G w" a7 x8 P) i4 J# T |